Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
The Boston Biotech Survival Index: Big Fish Still Swimming, Minnows Getting Eaten
|
Luke Timmerman |
10/08/09 |
Boston
|
|
Akamai And Delve Dig Into Online Video, Cardiorobotics Snags $11.6M for Snake-Like Surgery Robot, Longworth Collects $122M, & More Boston-Area Deals News
|
Rebecca Zacks |
08/07/09 |
Boston
|
|
Biotech Startup Acetylon Pharma Catches $7.25M in A Round from Backers Such As New England Patriots Owner
|
Ryan McBride |
08/07/09 |
Boston
|
|
Ariad Raises $30.9M
|
Luke Timmerman |
08/04/09 |
Boston
|
|
Joule Debuts Biofuel Technology, Genzyme Cleans House, Avila Banks $30M, & More Boston-Area Life Sciences News
|
Rebecca Zacks |
07/29/09 |
Boston
|
|
Ariad Shares Boom as Cancer Drug Shows Promise
|
Luke Timmerman |
07/28/09 |
Boston
|
|
Vertex Puts up $375M for ViroChem, Nuance Finally Nabs Zi, Proteon Procures $38M, & More Boston-Area Deals News
|
Rebecca Zacks |
03/06/09 |
Boston
|
|
Synta Melanoma Drug Trial Halted, Drug Regulators Hand Genzyme Mixed Bag, Ariad and ImmunoGen Reach Milestones, & More Boston-Area Life Sciences News
|
Rebecca Zacks |
03/04/09 |
Boston
|
|
Ariad Gets $10M From Merck
|
Luke Timmerman |
03/02/09 |
Boston
|
|
Ariad Arranges for Another $24.3M, Dismal Economy Doesn’t Stop Aveksa and Apparent Networks, Selecta Biosciences Chooses to Reveal Itself, & More Boston-Area Deals News
|
Rebecca Zacks |
02/27/09 |
Boston
|
|
Alnylam’s Spinoff Strategy, Genzyme’s Gaucher-Business Future, Adimab’s Antibody Ambitions, & More Boston-Area Life Sciences News
|
Rebecca Zacks |
02/25/09 |
Boston
|
|
Ariad Pharma to Sell $24.3M in Stock
|
Ryan McBride |
02/20/09 |
Boston
|
|
Novartis Deal Could Boost Ascent by $200M, Ariad’s Boardroom Drama Comes to Light, Targanta Takes Another Hit, & More Boston-Area Life Sciences News
|
Rebecca Zacks |
12/10/08 |
Boston
|
|
Ariad CEO Fires Back at Resigning Directors and Their “False and Misleading” Attacks
|
Luke Timmerman |
12/08/08 |
Boston
|
|
Ariad Directors Resign En Masse, Accuse CEO of “Grossly Inappropriate” Behavior
|
Luke Timmerman |
12/05/08 |
Boston
|
|
Biotech Survival Index: Boston Life Sciences Companies Brace for Long, Hard Winter
|
Luke Timmerman |
11/25/08 |
Boston
|
|
Vertex, Ariad, and Infinity Reach Clinical Milestones; FDA Grants Dying Cancer Patient Access to Tysabri; Genzyme Exec Takes Pervasive Helm; & More Boston-Area Life Sciences News
|
Rebecca Zacks |
10/22/08 |
Boston
|
|
Ariad Gets $12.5M From Merck For Beginning Cancer Trial
|
Luke Timmerman |
10/20/08 |
Boston
|
|
Sirtris Settles in at GSK, Alnylam Raises IP Questions on Bio Bill, Targanta Takes on Cubist’s Market, & More Life Sciences News
|
Rebecca Zacks |
09/24/08 |
Boston
|
|
Ariad Loses Patent Case Against Amgen
|
Luke Timmerman |
09/22/08 |
Boston
|
|
Pharmas Flock to Sermo, Biogen Idec Takes Another Tack with MS, $400M More for the Broad Institute, & More Life Sciences News
|
Rebecca Zacks |
09/04/08 |
Boston
|
|
Ariad Pharmaceuticals Edging Toward Becoming a Commercial Cancer Drug Company
|
Luke Timmerman |
09/02/08 |
Boston
|
|
Vertex Cystic Fibrosis Program on the Rise, Biogen and Partner Fall on Tysabri News, Alnylam Stakes RNAa IP Claim, & More Life Sciences News
|
Rebecca Zacks |
08/06/08 |
Boston
|
|
Ariad Begins Clinical Trial of Breast Cancer Drug
|
Luke Timmerman |
07/30/08 |
Boston
|
|
Ariad Staffs Up In Anticipation of Growth
|
Malorye Allison |
11/27/07 |
Boston
|
|
Page 1 of
1 |
|
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
